Other Revenue (Non-Cash) was Tvardi Therapeutics’s largest product and service line in fiscal 2024, bringing in $7.16M of $14.94M (48%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| License & Milestone Fees | $20.03M | — | $15.00M | $2.36M | — | |||||
| Collaborative Revenue | $706.00K | — | $16.57M | $13.48M | $2.09M | |||||
| Commercial Supply Revenue | $701.00K | — | $10.22M | $5.84M | $640.00K | |||||
| Other Revenue (Non-Cash) | — | — | — | $1.11M | $7.16M | |||||
| Commercial Supply Revenue With Associated Costs Of Goods Sold | — | — | — | $5.84M | $640.00K | |||||
| Other Revenue | — | — | — | $699.00K | $4.33M | |||||
| Commercial Supply Revenue With No Associated Costs Of Goods Sold | $701.00K | $2.30M | — | — | — | |||||
| Clinical Compound Revenue | $759.00K | — | — | $165.00K | $84.00K | |||||
| Other Non-Cash Revenue | — | — | — | $284.00K | — | |||||
| Royalty Revenue | — | — | $72.00K | $415.00K | — | |||||
| Total | $22.90M | $2.30M | $41.87M | $30.20M | $14.94M |
Tvardi Therapeutics brought in $14.94M from its six product and service lines in fiscal 2024, the year ended December 31, 2024. Tvardi Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $30.20M. Other Revenue (Non-Cash) was the largest at $7.16M (47.9%), ahead of Other Revenue at $4.33M (29.0%) and Collaborative Revenue at $2.09M (14.0%). The other three lines brought in $1.36M combined.
Compared with fiscal 2023, Other Revenue (Non-Cash) grew fastest, up 542.9% to $7.16M, while Commercial Supply Revenue With Associated Costs Of Goods Sold fell the most, down 89.0% to $640.00K.
Tvardi Therapeutics began breaking out Other Revenue (Non-Cash) in fiscal 2023, Commercial Supply Revenue With Associated Costs Of Goods Sold in fiscal 2023 and Other Revenue in fiscal 2023. Tvardi Therapeutics stopped reporting License & Milestone Fees ($2.36M in fiscal 2023), Commercial Supply Revenue With No Associated Costs Of Goods Sold ($2.30M in fiscal 2022), Royalty Revenue ($415.00K in fiscal 2023) and one other as separate lines.
Maruishi Agreement was Tvardi Therapeutics’s largest revenue line in fiscal 2024, bringing in $2.84M of $4.33M (66%).
| Research And Development Arrangement Contract To Perform For Others By Type | FY 2020 | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 | — | — | — | |
| Csl Vifor | $20.03M | — | — | |
| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 | $361.00K | — | — | |
| Maruishi Agreement | $1.19M | $2.36M | $2.84M | |
| Csl Vifor Kapruvia | — | $415.00K | $1.49M | |
| Csl Vifor Korsuva | $701.00K | — | — | |
| Ckdp Agreement | — | — | — | |
| Csl Vifor (Difelikefalin Injection) | $361.00K | — | — | |
| Total | $22.65M | $2.77M | $4.33M |
Tvardi Therapeutics brought in $4.33M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. That is less than the $14.94M it reports by product and service, so these revenue lines do not cover all of its revenue. Maruishi Agreement was the largest at $2.84M (65.5%), ahead of Csl Vifor Kapruvia at $1.49M (34.5%).
Compared with fiscal 2023, Csl Vifor Kapruvia grew 259.5% to $1.49M and Maruishi Agreement grew 20.2% to $2.84M.
Tvardi Therapeutics began breaking out Csl Vifor Kapruvia in fiscal 2023, when it brought in $415.00K. Tvardi Therapeutics stopped reporting Csl Vifor ($20.03M in fiscal 2021), Csl Vifor Korsuva ($701.00K in fiscal 2021), Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 ($361.00K in fiscal 2021) and one other as separate revenue lines.
Csl Vifor was Tvardi Therapeutics’s largest revenue line in fiscal 2020, bringing in $133.81M of $134.97M (99%).
| Related Party Transaction | FY 2016 | FY 2017 | FY 2019 | FY 2020 |
|---|---|---|---|---|
| Csl Vifor | — | — | $133.81M | |
| Vifor Fresenius Medical Care Renal Pharma Ltd | — | $19.75M | — | |
| Chong Kun Dang Pharmaceutical Corp | — | — | $626.00K | |
| Maruishi Pharmaceutical Co., Ltd | $530.00K | $140.00K | $528.00K | |
| Total | $530.00K | $19.89M | $134.97M |
Tvardi Therapeutics brought in $134.97M from its three revenue lines in fiscal 2020, the year ended December 31, 2020. Tvardi Therapeutics regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $19.89M. Csl Vifor was the largest at $133.81M (99.1%), ahead of Chong Kun Dang Pharmaceutical Corp at $626.00K (0.5%) and Maruishi Pharmaceutical Co., Ltd at $528.00K (0.4%).
Tvardi Therapeutics began breaking out Csl Vifor in fiscal 2020 and Chong Kun Dang Pharmaceutical Corp in fiscal 2020. Tvardi Therapeutics stopped reporting Vifor Fresenius Medical Care Renal Pharma Ltd as a separate revenue line after fiscal 2019, when it brought in $19.75M.
Tvardi Therapeutics (TVRD) reports its revenue by product and service, by research and development arrangement contract to perform for others by type and by related party transaction. In fiscal 2024, Other Revenue (Non-Cash) was its largest product and service line, bringing in $7.16M (47.9% of the total), followed by Other Revenue at $4.33M (29.0%).
Other Revenue (Non-Cash) was Tvardi Therapeutics' largest product and service line in fiscal 2024, bringing in $7.16M, or 47.9% of the $14.94M total across its six product and service lines.
Maruishi Agreement was Tvardi Therapeutics' largest revenue line in fiscal 2024, bringing in $2.84M, or 65.5% of the $4.33M total across its two revenue lines.
Csl Vifor Kapruvia grew faster than Maruishi Agreement in fiscal 2024, up 259.5% from $415.00K to $1.49M. Maruishi Agreement grew 20.2% to $2.84M.
Every figure comes from Tvardi Therapeutics' annual financial filings, as reported. Each line keeps the name Tvardi Therapeutics gives it, and years follow its fiscal calendar.
Tvardi Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.